Nurix Therapeutics NRIX Ratios (2019-2026)

NASDAQ NRIX
$26.02 -0.08 (-0.31%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

Nurix Therapeutics Quarterly Ratios

Periods 29 quarters
Latest Aug 2026

Nurix Therapeutics reported a net margin of 81.69% for the quarter ended Aug 2026. These financial ratios cover 29 quarters of results from Aug 2019 through Aug 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Feb2022 May2022 Aug2022 Nov2022 Feb2023 May2023 Aug2023 Nov2023 Feb2024 May2024 Aug2024 Nov2024 Feb2025 May2025 Aug2025 Nov2025 Feb2026 May2026 Aug2026
Profitability
EBT Margin
-509.17%-442.09%-397.14%-423.58%-688.74%-321.11%-79.14%-200.26%-276.77%-249.79%-367.65%-388.26%-440.69%-305.38%-96.93%-1,094.77%-576.13%-1,394.34%-993.10%83.71%
EBIT Margin
-513.16%-444.28%-399.89%-432.93%-717.82%-338.60%-87.25%-216.67%-299.06%-272.65%-401.42%-433.83%-486.73%-340.67%-109.68%-1,157.65%-612.03%-1,479.45%-1,041.73%83.12%
EBITDA Margin
-502.79%-433.98%-388.51%-419.03%-693.96%-324.79%-81.07%-206.10%-286.30%-260.32%-382.15%-414.82%-467.54%-327.94%-104.59%-1,131.96%-596.41%-1,444.32%-1,016.80%83.44%
Operating Margin
-513.16%-444.28%-399.89%-432.93%-717.82%-338.60%-87.25%-216.67%-299.06%-272.65%-401.42%-433.83%-486.73%-340.67%-109.68%-1,157.65%-612.03%-1,479.45%-1,041.73%83.12%
Net Margin
-509.76%-442.09%-397.14%-423.58%-688.74%-321.11%-79.14%-200.26%-276.77%-250.33%-368.39%-388.91%-440.75%-305.38%-98.66%-1,094.77%-576.13%-1,394.34%-990.10%81.69%
FCF Margin
-429.60%-479.18%-312.31%-460.81%-597.38%-399.91%-63.73%-236.05%159.01%-270.33%-344.38%-353.70%-382.84%-349.93%-149.44%-761.29%-537.40%-1,166.97%-1,089.34%91.26%
Efficiency
Assets AverageAssets Avg.
484.92M457.25M416.02M426.82M438.05M393.46M360.39M329.41M331.90M334.14M411.85M512.32M591.47M642.19M603.30M557.01M605.30M662.13M585.84M865.42M
Equity AverageEquity Avg.
358.76M324.11M286.33M304.64M323.12M288.87M266.99M246.87M217.16M184.62M269.72M373.77M451.92M503.96M464.26M409.93M455.50M509.82M441.76M685.47M
Asset Utilization RatioAsset Util.
0.060.080.090.090.090.110.170.210.230.240.150.110.090.090.150.150.140.110.060.81
Valuation
Price to SalesP/S
4.01
Price to EarningsP/E
9.55
Price to BookP/B
2.91
Enterprise Value
1,766.93M
Market Capitalization
2,815.19M
EV to EBIT
6.10
Price to FCFP/FCF
7.61
EV to EBITDA
5.92
EV to FCF
4.78
EV to CFO
4.66
Return Ratios
Return on Sales [ROS]ROS
83.12%
Return on Capital Employed [ROCE]ROCE
39.43%
Return on Assets [ROA]ROA
34.08%
Return on Equity [ROE]ROE
43.02%

Nurix Therapeutics Ratios API

Pull Nurix Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NRIX&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY